PMID 12195242
"Brightening" vs
TRIUMPH-4 (retatrutide, 68 weeks): Discontinuation due to AEs: 12.2% (9 mg), 18.2% (12 mg) vs 4.0% placebo Key characteristics: Highest GI adverse event rates among the drugs compared here Dysesthesia is a novel safety signal -- abnormal touch sensations affecting up to 21% at the 12 mg dose, not seen in Phase 2
At Alloy, compounded tirzepatide is prescribed by menopause-trained physicians who can tailor treatment to your specific tolerance, goals, and body composition, including by starting you at lower doses and adjusting more gradually, where appropriate
Stadlbauer V, Mookerjee RP, Hodges S, Wright GA, Davies NA, Jalan R
ESTHETICS BODY Laser Hair Removal Experience the ultimate hair removal solution for smooth, silky, and hair-free skin